logo
Plus   Neg
Share
Email

AstraZeneca: FDA Grants Priority Review For Imfinzi - Quick Facts

AstraZeneca plc (AZN.L,AZN) announced the US FDA has accepted a supplemental Biologics License Application and granted Priority Review for Imfinzi for the treatment of patients with previously untreated extensive-stage small cell lung cancer. The sBLA was based on positive results from the Phase III CASPIAN trial. The PDUFA date is set for the first quarter of 2020.

Imfinzi is approved in the curative-intent setting of unresectable, Stage III non-small cell lung cancer after chemoradiation therapy in 54 countries, including the US, Japan and the EU.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Online-video streaming giant Netflix Inc. (NFLX), Tuesday reported a fourth-quarter profit that trounced Wall Street estimates, as revenues surged 31% driven by strong subscriber growth. Netflix added 8.76 million subscribers globally in the quarter, above its forecast of 7.60 million, to end the... Fast food chain Krystal Company has filed for bankruptcy, according to reports. The Atlanta-based Krystal filed for Chapter 11 on Sunday in the U.S. Bankruptcy Court in Atlanta. In the filing, the company reportedly disclosed assets between $10 million and $50 million, and liabilities between $50 million and $100 million. The chief executive officer of Google's parent company Alphabet called for artificial intelligence or AI to be regulated, noting that there are real concerns about the potential negative consequences of the technology. According to Alphabet CEO Sundar Pichai, there are real concerns about the negative consequences of AI, from deepfakes to nefarious uses of facial recognition.
Follow RTT
>